Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BUZZ - Australia's EVT stock rises due to first-quarter EBITDA growth

BUZZ - Australia's EVT stock rises due to first-quarter EBITDA growth

路透社路透社2026/10/23 01:30
Show original

- ** EVT (EVT.AX) shares rose as much as 4% to AUD 15.490, reaching their highest level since August 26

** The stock recorded its largest intraday gain since September 25

** The entertainment company announced (link) first quarter FY2027 EBITDA of AUD 72.5 million, a 17% year-on-year increase on a normalized basis

** EVT maintains an optimistic outlook for FY2027 and expects the hotels business to reach a historic high

** The company expects FY2027 EBITDA for Thredbo Alpine Resort to be between AUD 16 million and AUD 20 million, compared to Visible Alpha's analyst consensus of AUD 16.9 million; the FY2026 figure was AUD 21 million

** Citi rates the stock as "Buy" with a target price of AUD 17.55

** Year-to-date, the share price has risen 19.5%


(To assist non-native English speakers, Reuters has automated the translation of its reports into several other languages. Because automated translation may contain errors or may not include necessary context, Reuters does not guarantee the accuracy of the automated translation and provides it for readers' convenience only. Reuters assumes no responsibility for any damage or loss caused by the use of this automated translation function.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Chinese 3D vision AI startup Sensing4D AI submits IPO application to US stock market: plans to raise $35 million and advance embodied intelligence simulation.

Sensing4D AI plans to go public on Nasdaq, aiming to raise $35 million, with a primary focus on 3D reconstruction and embodied intelligence simulation. The company's annual revenue is $29 million.

智通财经•2026/10/23 08:57

Rezera (RZRA.US) submits IPO application: Oral NLRP3 inhibitor pipeline progresses, Phase 3 PAD trial scheduled to begin in 2027

Rezera plans to go public on Nasdaq to raise 100 millions USD. Its oral NLRP3 inhibitor will initiate a Phase III trial for PAD, with data expected in 2028.

智通财经•2026/10/23 08:32